Vifor Pharma – part of the Galenica Group – has gained rights to commercialise rare avacopan in Asia, including Japan and the Middle East, from ChemoCentryx.
Avacopan (CCX168) is an orally-administered inhibitor of the complement 5a receptor (C5aR) and is currently in Phase III development for rare renal diseases.
ChemoCentryx retains all rights in the United States and China, as well as remaining responsible for worldwide development of the treatment.
The expanded agreement effectively gives Vifor Pharma rights to commercialise avacopan for orphan and rare renal diseases in all markets outside the United States and China, building on the original licensing agreement signed in May 2016.
ChemoCentryx will receive an upfront cash commitment of $20 million in return for the new rights, plus tiered double-digit royalties on potential net sales. This is in addition to the $85 million upfront paid under the original May 2016 licensing agreement.
Avacopan is being developed by ChemoCentryx for the treatment of orphan and rare renal conditions including but not limited to anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis (AAV).
AAV is a systemic disease which most commonly presents as kidney dysfunction. AAV is currently treated with courses of non-specific immuno-suppressants, combined with high-dose corticosteroid administration, which is associated with significant safety issues, including premature death.
Avacopan is in Phase III development for the treatment of AAV and is also in development for other orphan and rare renal diseases, including C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS).